Investigator Grant Payments

INVESTIGATOR GRANT PAYMENTS ARTICLES

INVESTIGATOR GRANT PAYMENTS WHITE PAPERS AND CASE STUDIES

INVESTIGATOR GRANT PAYMENTS PRODUCTS & SERVICES

Critical in almost every step of viral vector and gene therapy manufacturing processes as well as fundamental aspects of cell therapy process development, buffers are essential tools enabling optimization of vector stability, transfection efficiency, safety, targeting, and regulatory compliance.

Qosina carries an assortment of single-use swabs that can be used in all types of applications, across multiple industries.

Decode 3D biology in real time*

The THUNDER Imager Model Organism allows fast and easy 3D exploration of whole organisms for developmental or molecular biology research. Thanks to THUNDER Live, your images reveal the finest structural details already in the live image. No hassle with out-of-focus blur while maintaining the capabilities and ease-of-use typical for Leica stereo microscopes.

A THUNDER Imager Model Organism is the optimal instrument for studying, e.g., Drosophila, C. elegans, zebrafish, plants, and mice. One device for screening, positioning, and imaging your specimen. Simplify your workflow and study model organisms from a large overview to the highest detail.

The QTRAP 4500 System offers reliable quantitation and library searching - with 100X more full-scan sensitivity over basic triple quads in the same class.

Iron salts are a proven technology for long-duration hydrogen sulfide control in collection system gravity and forcemains; solids processing units, solids transfer lines and anaerobic digesters. They have been used for over 30 years in hydrogen sulfide control applications and are a well understood technology.

Sikich SuiteExpress expedites NetSuite implementation at a fraction of the typical cost companies see when deciding to switch ERPs, offering early-stage companies a much quicker way to implement NetSuite.

The next generation in bioprocess control

The Livit Flex is the intuitive controller that fits any research and development application. It can be configured as a single or dual control system for single-use and / or multi-use bioreactors. Only one network is needed to monitor and control the data of all your bioprocesses.

Leverage our team of expert cell media scientists to develop, refine, and deliver a complete formula tailor-made to your specifications. A concierge approach to custom media design.

INVESTIGATOR GRANT PAYMENTS NEWS

ABOUT

Investigator Grant Payments
In the clinical trials industry, there is usually the pressure of making profits while maintaining regulatory compliance. In order to maximize on their research and development spending, pharmaceutical companies are reducing clinical trial cycle times.
However, there are an increasing number of clinical trials, with more complex protocols and more stringent regulatory requirements. Despite all these, many sponsors issue late payments to investigative sites, and many of these sites are struggling to maintain financial viability.
If the sponsors want to maintain strong, effective investigative sites, they need to build strong relationships with them. This involves coming up with a more effective approach to investigator grant payments. This will not only improve investigator relationships and satisfaction, it will help sponsors to accelerate cycle times and reduce the costs of clinical trials.
First, there is a need to understand that accounts payable in the clinical trials industry are very complex. Investigator grant payments are driven by the terms of the clinical trial agreement. These agreements are highly complex documents with various variables that can impact on the grant payment.
There is also a need for better management of investigator grant payments through the right personnel. Apart from having a background in finance and accounting, those in charge ought to have some experience in financial management of clinical trials.
Such a person would understand the standard process for a clinical trial, from screening to treatment of patients. He or she should be able to read and understand how the clinical study is progressing against the clinical trial agreement.